US · CBIO
Crescent Biopharma, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Waltham, MA 02451
- Website
- crescentbiopharma.com
Price · as of 2025-12-31
$18.07
Market cap 333.16M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $25.76 | $901.92 | |||
| 2013 | -$1,731.40 | -$496.37 | $0.00 | $0.00 | $554.03 |
| 2014 | -$904.20 | -$280.39 | $160,500.73 | $0.00 | $0.00 |
| 2015 | -$623.70 | -$222.90 | $1,294.11 | $0.00 | $0.00 |
| 2016 | -$712.80 | -$254.82 | $0.18 | $0.00 | $130.97 |
| 2017 | -$1,961.30 | -$753.38 | |||
| 2018 | -$1,236.40 | ||||
| 2019 | -$381.70 | ||||
| 2020 | -$364.10 | $19.03 | $0.00 | ||
| 2021 | -$121.00 | -$20.40 | $1.77 | $0.00 | $94.45 |
| 2022 | $131.00 | $83.81 | $0.00 | $0.00 | $72.35 |
| 2023 | $273.00 | $141.05 | $0.00 | $0.00 | $43.52 |
| 2024 | $27.00 | $43.87 | |||
| 2025 | $11.20 |
AI valuation
Our deep-learning model estimates Crescent Biopharma, Inc.'s (CBIO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $18.07
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CBIO | Crescent Biopharma, Inc. | $18.07 | 333.16M | — | — | — | — | -7.78 | 5.75 | — | -6.38 | 0.00 | 5.75 | 0.00% | — | — | -143.95% | 59483.26% | -108.69% | 0.01 | -69.85 | 6.56 | 6.41 | 1.41 | 217244407.00% | — | 13290.00% | -6.21% | -1.98 | 28611.99% | 0.00% | 0.00% | 18.37% | -6.26 | -13.18 | — | 16.68 |
| CCCC | C4 Therapeutics, Inc. | $2.70 | 192.18M | +704% | -21% | — | — | -2.50 | 1.02 | 7.31 | -0.72 | — | 1.02 | 77.81% | -290.68% | -292.08% | -44.44% | -199.27% | -29.63% | 0.23 | — | 7.81 | 7.60 | 0.14 | -1645.00% | 102.00% | 5198.00% | -37.79% | -2.99 | -189.38% | 0.00% | 0.00% | 9.54% | -0.71 | -0.75 | 2.06 | -1.45 |
| CGEN | Compugen Ltd. | $1.81 | 169.3M | +2,407% | -50% | — | -30% | -10.44 | 2.71 | 5.33 | -3.35 | — | 2.71 | 71.54% | -53.44% | -51.07% | -23.63% | 101.98% | -12.04% | 0.05 | -437.97 | 5.26 | 5.14 | 1.06 | -2381.00% | -1672.00% | -23724.00% | 33.30% | 2.46 | -338.90% | 0.00% | 0.00% | 1.87% | -3.24 | 0.98 | 1.73 | -3.76 |
| HIND | Vyome Holdings, Inc. | $3.37 | 19.02M | +1,072,047% | +974% | — | — | -0.26 | -7.38 | 0.23 | -0.32 | — | -7.38 | 63.17% | -96.53% | -89.06% | -222.46% | -647.51% | -91.88% | -3.82 | — | 0.92 | 0.35 | -0.04 | -8753.00% | -774.00% | -7396.00% | -237.21% | -0.89 | -370.93% | 0.00% | 0.00% | 0.00% | -0.28 | -0.48 | 0.27 | -191.26 |
| HRTX | Heron Therapeutics, Inc. | $1.19 | 187.95M | +2,066% | -60% | — | — | -9.91 | 13.96 | 1.29 | -16.45 | -28.56 | 13.96 | 73.31% | -1.64% | -13.04% | 209.08% | -2.63% | -8.26% | 9.81 | — | 2.48 | 1.42 | -6.26 | 3468.00% | 736.00% | 1516.00% | -13.95% | -0.29 | -28.89% | 0.00% | 0.00% | 19.98% | -115.86 | -10.54 | 1.90 | -8.88 |
| IMDX | Insight Molecular Diagnos… | $6.01 | 172.27M | +228% | -74% | — | — | -0.84 | -4.15 | 27.10 | -0.78 | -3.46 | -1.90 | 39.34% | -3245.14% | -3225.04% | -1480.67% | 3654.06% | -110.32% | -0.30 | -726.68 | 1.62 | 1.41 | 0.08 | 2430.00% | 2515.00% | -1007.00% | -41.64% | -2.85 | 1270.82% | 0.00% | 0.00% | 0.00% | -0.75 | -2.17 | 24.46 | -18.88 |
| IPHA | Innate Pharma S.A. | $1.72 | 160.74M | +2,263% | -50% | — | +2,571% | -2.98 | 16.70 | 11.69 | -2.08 | -0.52 | 16.70 | 100.00% | -408.64% | -391.97% | -162.91% | 247.94% | -34.57% | 3.51 | -91.12 | 2.60 | 2.50 | 0.75 | 57778.00% | -7568.00% | -7913.00% | -4.94% | -0.21 | 35.03% | 0.00% | 0.00% | 3.18% | -1.90 | -13.41 | 7.74 | -4.85 |
| OABI | OmniAb, Inc. | $1.72 | 185.11M | +16,336% | +3% | — | +382% | -5.61 | 1.21 | 13.19 | -6.12 | -28.61 | 5.31 | 100.00% | -282.30% | -235.05% | -20.60% | -25.66% | -17.70% | 0.08 | — | 4.52 | 4.29 | 0.09 | 1961.00% | -2275.00% | -600882.00% | -11.94% | -2.63 | -16.47% | 0.00% | 0.00% | 3.92% | -4.18 | -7.51 | 11.81 | 4.59 |
| SGMO | Sangamo Therapeutics, Inc… | $0.43 | 160.68M | +6,900% | -3% | — | +6,207% | -2.14 | 9.21 | 3.63 | -2.23 | — | 9.21 | 100.00% | -179.88% | -169.45% | -185.39% | -403.81% | -73.38% | 1.34 | — | 1.13 | 1.02 | 0.13 | -6689.00% | -6720.00% | -7260.00% | -32.13% | -1.47 | -262.24% | 0.00% | 0.00% | 2.03% | -1.91 | -2.94 | 3.43 | -21.86 |
| TNXP | Tonix Pharmaceuticals Hol… | $13.97 | 178.65M | -2% | -63% | — | — | -0.23 | 0.21 | 2.92 | 0.86 | — | 0.21 | 23.07% | -1354.28% | -1288.25% | -106.12% | -200.34% | -81.95% | 0.04 | — | 6.50 | 5.83 | 1.26 | -9723.00% | 2994.00% | -4445.00% | -207.14% | -3.33 | -89.46% | 0.00% | 0.00% | 265.83% | 0.47 | 1.05 | -6.34 | -7.49 |
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
- CEO
- Joshua T. Brumm
- Employees
- 41
- Beta
- 1.30
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $18.07) − 1 = — (DCF, example).